期刊文献+

64排螺旋CT动态增强扫描对膀胱移行细胞癌T分期的诊断价值 被引量:2

原文传递
导出
摘要 目的探讨64排螺旋CT(MDCT)动态增强扫描对膀胱原发性移行细胞癌(TCC)术前分期的准确性。方法根据MDCT动态增强扫描肿瘤浸润范围及其强化CT值的动态变化,对42例病理证实为TCC的患者进行术前CT分期,并与术后病理分期进行对照。结果 MDCT动态增强扫描对TCC术前分期的总准确率为94.8%,对膀胱壁内癌灶(≤T2b期)分期的准确率为92.9%,对侵犯壁外结构肿瘤(≥T3)分期的准确率为97.6%;T1/T2期与T3/T4期癌灶CT强化均值比较:动脉期及延迟期差异有统计学意义(均P<0.05),静脉期差异无统计学意义(P>0.05)。结论 MDCT动态增强扫描有助于显示肿瘤浸润范围及其强化CT值的动态变化,从而有助于提高TCC术前分期的准确性。
出处 《苏州大学学报(医学版)》 CAS 2012年第5期733-736,共4页 Suzhou University Journal of Medical Science
  • 相关文献

参考文献11

  • 1刁显明,王学华,李启虎.螺旋CT对原发性膀胱移行细胞癌分期的评价[J].华西医学,2010,25(8):1489-1491. 被引量:1
  • 2Sagol 0, Yorukoglu K, Sis B,et al. Dose angiogenesis per-dict recurrence in superficial transitional cell carcinoma ofthe bladder[ J] Urolgy,2001,57(5) :895 -899.
  • 3谢琦,张静,江新青,陈胜利,王奇玲,许进,古杰洪,郑一君.膀胱移行上皮癌螺旋CT增强扫描与肿瘤血管生成的相关性研究[J].中华肿瘤杂志,2003,25(6):569-572. 被引量:7
  • 4郝楠馨,诸静其,王葳,曹开明,杜育杉,汪波.多层螺旋CT对膀胱癌的诊断价值[J].中国医学计算机成像杂志,2010,16(2):135-138. 被引量:15
  • 5Jinzaki M,Tanimoto A, Shinmoto H,et al. Detection of blad-der tumors with dynamic contrast-enhanced MDCT [ J]AJR,2007,188(4) :913-918.
  • 6Fritz GA, Schoellnast H, Deutschmann HA, et al. Mul-tiphasic multidetectorrow CT ( MDCT) in detection andstaging of transitional cell carcinomas of the upper urinarytract[ J] . Eur Radiol,2006,16(6) :1244 - 1252.
  • 7许彪,陈刚,韦璐.多层螺旋CT在膀胱癌诊断及CT分期中的应用价值[J].实用放射学杂志,2007,23(7):995-998. 被引量:7
  • 8Zhang J,Gerst SI,Efkowitz RA,et al. Imaging of bladdercancer [ J] Radiol Clin North Am, 2007 , 45 ( 1 ) : 183-205.
  • 9Kim JK,Park SY,Ahn HJ,et al. Bladder cancer:analysis ofmulti detecter row helical CT enhancement pattern and ac-curacy in tumor detection and perivesical staging[ J] Radi-ology ,2004,231 (3) :725 -731.
  • 10Kim CS, Kim SH, Lee HJ, et al. Clinical significance ofbladder urothelial thickening and enhancement revealed onMDCT urography after transurethral resection of tumor[J] Computer Assisted Tomography,2012 , 36 ( 2 ) : 243-248.

二级参考文献29

  • 1宁永见,郭友,付莉萍,陈曌,王晓文.膀胱移行细胞癌术前CT与病理分期对照分析[J].中国临床医学影像杂志,2004,15(7):387-390. 被引量:9
  • 2刘定益,陈其智,唐敖荣,黄群.膀胱癌术前CT临床分期的评价[J].中华外科杂志,1996,34(5):283-285. 被引量:9
  • 3黎喜,谢增海,王博生.膀胱癌的CT分期与病理对照[J].实用医学影像杂志,2005,6(4):225-226. 被引量:7
  • 4修建军,崔允峰,刘庆伟,赵素红,李轶新,张伟.几种CT检查方法对发现膀胱肿瘤价值的比较[J].实用放射学杂志,2006,22(3):321-325. 被引量:4
  • 5Lawrence FB, Brygida B, Robert WR, et al. Increased expression of vascular permeability factor(vascular endothelial growth factor) and its receptors in kidney and bladder carcinoma[J].AJP, 1993,143(5): 125-1262.
  • 6Takao M, Fukuda T, Iwanaga S, et al. Gastric cancer: evaluation of triphas-ic spiral CT and radiology pathologic correlation[J]. J ComputAssist Tomogr, 1998,22 (2) : 288-294.
  • 7King AD, Ko GTC, Yeung VTF, et al. Dual phasse spiral CT in the detect-ion of small insulinomas of the pancreas [J]. BJR, 1998,71(1) :20-23.
  • 8Sagol O, Yorukoglu K, Sis B, et al. Does angiogenesis predict recurrence in superficial transitional cell carcinoma of the bladder [J]. Urology,2001,57(5) :895-899.
  • 9Paik ML, Scolieri MJ, Brown SL,et al. Limitation of computerized tomography in staging invasive bladder cancer before radical cystectomy [J]. Jurol,2000,163(6) : 1693-1696.
  • 10Ryuji M, Hideo N, Hiroshi Y,et al. Correlation of antiangi-ogenic and antitumor efficacy of N-biphenyl sulfonyl-pheny-lalamine hydroxiamic acid (BPHA), an orally-active, selective matrixmet-alloprot-einase inhibitor [J].Cancer Res, 1999, 59 ( 6 ): 1231-1235.

共引文献23

同被引文献20

  • 1Lin J, Deibert CM, Holder D ,et al. The role of pelvic lymphadenec- tomy in non-muscle invasive bladder cancer [ J ]. Can J Urol,2014, 21 ( 1 ) :7108-7113.
  • 2Kaba M, Pifincci N, Benli E, et al. Dickkopf-1 levels in Turkish patients with bladder cancer and its association with clinicopatho- logical features [ J ]. Asian Pac J Cancer Prev, 2014, 15 ( 1 ) : 381-384.
  • 3Fleisehmann A, Thalmoam GN, Perren A, et al. Tumor regression grade of urothelial bladder caneer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival [ J ].Am J Surg Pathol,2014,38 (3) :325-332.
  • 4Cohn JA, Vekhter B, Lyttle C, et al. Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nation- wide claims-based investigation [ J ]. Cancer, 2014, 120 ( 4 ) : 555-561.
  • 5Oude Elferink P,Witjes JA. Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer[ J]. Ther Adv Urol,2014,6 ( 1 ) :25-33.
  • 6Morrison CD, Liu P, Waloszynska-Read A, et al. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer[ J]. Proc Natl Acad Sci U S A,2014,111 (6) :672-681.
  • 7Siegel R, Naishadlam D, Jemal A. Cancer statistics,2012. CA Cancer J Clin ,2012,62 : 10.
  • 8Sylvester R J, van der Meijden AP, Oosterlinck W, et al. Prediciting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol,2006 ,49 :466.
  • 9Jichlinski P, Leisinger HJ. Fluorescence cystoscopy in the manage- ment of bladder cancer : a help for the urologist. Urol Int, 2005,74 : 97.
  • 10Joudi FN, Konety BR. Fluoreseence eystoscopy and bladder surveil- lance. Urol,2004,14:265.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部